My understanding after discussions with management is that NATA approval of the lab will mean they can sell their breastest commercially immediately and initially through the 10 to 12 clinics in NSW and Victoria who are already very keen to get going with huge support from clinical professional opinion leaders.
Bcal are conservatively expecting 16k to 30k tests in year 1. At $300 a pop.
They will need TGA approval to qualify for reimbursement. They can't get reimbursement without TGA approval.
The Breastest will be significantly cheaper than the cost of a mamogram to the gov't.
Bcal will use the same pathway in the USA which has a similar regulatory system.
Big 6 months coming up.
Ann: Company Presentation - Investor Insights, page-45
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BDX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
-0.005(4.00%) |
Mkt cap ! $37.71M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.5¢ | 11.5¢ | $87.75K | 723.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 11424 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 185875 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| BDX (ASX) Chart |